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Venous thromboembolism (VTE) is a potentially life-threatening 
medical condition. Pregnancy induces a hypercoagulable state 
with an increase in coagulation factors and a decrease in natural 
anticoagulants, which increases the risk of deep-vein thrombosis 
(DVT) and pulmonary embolism (PE) in ~0.5 - 2.2 per 1 000 preg-
nancies.[1] Furthermore, the puerperium is the time of maximal risk 
of pregnancy-associated VTE.
The use of thromboprophylaxis in patients at risk of VTE is 
of proven benefit, with low-molecular-weight heparin (LMWH) 
reducing VTE risk in medical and surgical patients by 60% and 
70%, respectively.[2] No adequately powered randomised controlled 
trials have investigated the efficacy and safety of pharmacological 
prophylaxis in pregnancy and the puerperium. However, VTE 
pharmacological prophylaxis is advocated by both international[3] 
and local guidelines,[4] and is regarded as the standard of care in the 
appropriate patient.
The absolute risk for VTE in pregnancy is low, and risk 
stratification is required to determine which patients would benefit 
from thromboprophylaxis.[3] There is a paucity of data on VTE risk 
stratification and thromboembolism prophylaxis in South African 
(SA) patients in general,[5] and specifically during pregnancy and the 
puerperium.
Objectives
To evaluate local practices with regard to VTE risk stratification 
and thromboembolism prophylaxis during pregnancy and the 
puerperium.
Methods
This study was a sub-analysis of patients who participated in the 
SAVE global study, the primary objective of which was to estimate 
the proportion of women at risk of VTE during pregnancy and 
the postpartum period among all women attending prenatal and/
or obstetric centres. Secondary objectives included determining 
the proportion of women at risk receiving an effective type of VTE 
prophylaxis according to the American College of Chest Physicians[6] 
and/or Royal College of Obstetricians and Gynaecologists (RCOG) [3] 
guidelines, analysing factors that drive the decision to provide 
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Background. Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Pregnancy and the puerperium are 
hypercoagulable states and increase the risk of VTE. There is a paucity of South African (SA) data related to use of thromboprophylaxis 
during pregnancy and the puerperium.
Objectives. To evaluate local practice of VTE risk stratification among SA pregnant women and senior doctors’ attitudes to VTE prophylaxis.
Methods. This was a cross-sectional descriptive study of conveniently sampled sites in the private and public health sectors. Patients with 
confirmed pregnancy and an underlying medical condition were enrolled after giving informed consent. Assessments were made based on 
the participating doctors’ questionnaires and case report forms. In essence, this was a local evaluation of a specific group of patients by a 
specific group of doctors.
Results. Two hundred and twenty patients were enrolled at six sites. In the participating doctors’ opinion, 126/220 women assessed (57.2%) 
were at risk of VTE during pregnancy and the postpartum period (information was missing for 1 woman during the postpartum period). 
Of the women at risk of VTE, 23/126 (18.3%) were at high risk, 59/126 (46.8%) at moderate risk and 44/126 (34.9%) at low risk. Of the 
women identified as at risk of VTE, 104/127 (81.9%) received some form of VTE prophylaxis; 94/127 (74.0%) were at risk during pregnancy 
and 32/126 (25.4%) during the postpartum period. Of those who received pharmacological treatment, 15/15 received low-molecular-weight 
heparin during pregnancy and before delivery and 87/100 during the puerperium. Thirty-four patients received thromboprophylaxis for 
only 5 - 10 days after caesarean delivery, and 2 received mechanical thromboprophylaxis during pregnancy.
Conclusions. Doctors participating in the study were generally aware of VTE risk during pregnancy and the puerperium. Pharmacological 
thromboprophylaxis was the most commonly used intervention to reduce VTE risk. Mechanical thromboprophylaxis was underutilised. 
Adherence to VTE guidelines, specifically in terms of duration of thromboprophylaxis and its utilisation during pregnancy, was suboptimal.
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prophylaxis, and determining the overall proportion of patients 
receiving mechanical v. pharmacological prophylaxis. The criteria for 
VTE risk assessment (high risk, intermediate/moderate and lower 
risk) are set out in Table 1.[3]
Study design and setting
The SAVE study was a non-interventional, cross-sectional descriptive 
study conducted in 18 countries from December 2014 to October 
2015. The primary study[7] has been reported, and this article 
describes the SA cohort. 
Criteria for selection of doctors and patients
A master list of doctors from SA was generated by the Sanofi 
clinical trials department. The list was based on the potential of the 
participating doctors to recruit the appropriate patients within the 
study timelines, and we attempted to obtain representation from both 
the SA public and private healthcare sectors. We then contacted each 
doctor on the master list and asked them to complete a site feasibility 
questionnaire to indicate their interest in the study and the number of 
patients they could potentially contribute to it.
Patients selected[7] were women aged >18 years with objectively 
confirmed pregnancy, visiting for the first prenatal consultation or 
any other consultation during pregnancy, with an underlying medical 
condition, with/without the need for pre-partum hospitalisation for 
medical reasons, and who were willing to participate. Patients excluded 
were women with a VTE event in the preceding 4 months or those 
using concurrent antithrombotic therapy for other medical reasons.
Information collected[7]
Information was collected via participating doctors’ questionnaires 
and case report forms and included patient demographics, history, 
reason/s for consultation and VTE risk stratification. Information on 
the doctors included demographics, specialty, and their evaluation of 
VTE risk stratification and management.
Sample size[7]
A detailed description of the statistical analysis can be found in 
the primary paper.[7] The local sample size was selected based on 
numbers needed in the original SAVE study.
Ethical considerations
The study received approval from the local ethics committees 
(Pharma-Ethics and the University of Pretoria ethics committee), and 
the study participants gave signed informed consent.
Results
Physician characteristics
There were six study sites staffed with 6 medical doctors participating 
in the study. The majority of the doctors were aware of the existence 
of guidelines for VTE (83.3, 5/6) with 3 following the guidelines. 
Reasons for not following the guidelines included lack of time and 
‘other’. The questionnaire did not allow for description of the local 
guideline, which may have been interpreted as a local institutionally 
based guideline or national guideline.
Patient disposition and characteristics
Of a total of 224 patients screened, 220 were considered eligible 
to participate in the study. The 4 screen failures were based on the 
participating doctor’s decision. Of the six study sites, 50% were 
public sector sites and 50% private sector sites. A total of 90 and 
130 patients were recruited from the private and public sector sites, 
respectively.
Table 1. VTE risk assessment in obstetrics
Risk category Risk factors
Antenatal assessment
High risk Any previous VTE other than a single event related to major surgery 
Intermediate/moderate risk Hospital admission; single previous VTE related to major surgery; high-risk thrombophilia and 
no VTE; medical comorbidities, e.g. cancer, heart failure, active systemic lupus erythematosus, 
inflammatory bowel disease or inflammatory polyarthropathy, nephrotic syndrome, type 1 diabetes 
mellitus with nephropathy, sickle cell disease; current intravenous drug user; any surgical procedure, 
e.g. appendicectomy; ovarian hyperstimulation syndrome (first trimester only)
Lower risk (<3 risk factors) Obesity (body mass index >30 kg/m2); age >35 years; parity ≥3; smoker; gross varicose veins; current 
pre-eclampsia; immobility, e.g. paraplegia, pelvic girdle pain with reduced mobility; family history 
of unprovoked or oestrogen-provoked VTE in first-degree relative; low-risk thrombophilia; multiple 
pregnancy; in vitro fertilisation/assisted reproductive technology; transient risk factors: dehydration/
hyperemesis, current systemic infection, long-distance travel
Postnatal assessment
High risk Any previous VTE; need for antenatal LMWH; high-risk thrombophilia; low-risk thrombophilia + 
family history
Intermediate/moderate risk Caesarean section in labour; body mass index ≥40 kg/m2; readmission or prolonged admission  
(≥3 days) in the puerperium; any surgical procedure in the puerperium other than repair of 
perineum; medical comorbidities, e.g. cancer, heart failure, active systemic lupus erythematosus, 
inflammatory bowel disease or inflammatory polyarthropathy, nephrotic syndrome, type 1 diabetes 
mellitus with nephropathy, sickle cell disease; current intravenous drug user
 Intermediate/moderate risk  
(≥2 risk factors) and lower risk  
(<2 risk factors)
Age >35 years; parity ≥3; smoker; elective caesarean section; family history of VTE; low-risk 
thrombophilia; gross varicose veins; current systemic infection; immobility, e.g. paraplegia, pelvic 
girdle pain with reduced mobility, long-distance travel; current pre-eclampsia; multiple pregnancy; 
preterm delivery in this pregnancy (<37 weeks); stillbirth in this pregnancy; mid-cavity rotational or 
operative delivery; prolonged labour (>24 hours); postpartum haemorrhage 
VTE = venous thromboembolism; LMWH = low-molecular-weight heparin.
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Of the 220 patients entered into the study, 172 (78.2%) were black. 
The mean (standard deviation (SD)) age of the cohort was 29.4 (5.9) 
years (Table 2). Thirty-two patients (14.5%) were HIV-positive, and 
98 (44.5%) were obese (Table 3). In the majority of cases (n=169, 
76.8%) the consultation was a routine visit (Table 4).
The majority of consultations were during pregnancy (n=183, 
83.2%), specifically the third trimester (n=89, 40.5%), with a mean 
(SD) gestation of 26.8 (9.1) weeks.
Proportion and intensity of VTE risk
According to the participating doctors, 126/220 patients (57.2%) 
were at risk of VTE during pregnancy and postpartum (information 
was missing for 1 woman during the postpartum period); of the 
pregnant patients, 94/127 (74.0%) were at risk, and of those in the 
in the puerperium, 32/126 (25.4%) were at risk. When the risk was 
stratified by intensity, 9/32 postpartum patients (28.1%) were at high 
risk. VTE risk stratification was missing for one patient. Table 5 sets 
out the risk stratification for women at risk of VTE during pregnancy 
and postpartum.
VTE prophylaxis
Of the 126 women at risk, 104 (82.5%) (95% confidence interval 
(CI) 74.08 - 88.16) were prescribed thromboprophylaxis, during 
pregnancy in 75/94 cases (79.8%) (95% CI 70.25 - 87.37) and 
Table 2. Patient demographics (N=220)
Age (years)
Mean (SD) 29.4 (5.9)
Median 29.0
IQR 25.0 - 33.0
Range 19 - 44
Age in groups (years), n (%)
≤20 12 (5.5)
20 - 30 124 (56.4)
31- 40 76 (34.5)
41 - 50 8 (3.6)
>50 0
18 - 35 179 (81.4)
>35 41 (18.6)
Ethnicity, n (%)
White 18 (8.2)
Black 172 (78.2)
South Asian 24 (10.9)
Other 6 (2.7)
SD = standard deviation; IQR = interquartile range.
Table 3. Concomitant medical conditions (N=220)
Medical condition n (%)
Chronic lung disease 5 (2.3)
Chronic heart disease 4 (1.8)
Chronic neurological disease 3 (1.4)
Nephrotic syndrome (proteinuria >3 g/24 h) 6 (2.7)
HIV infection 32 (14.5)
Active cancer 1 (0.5)
Short-term immobilisation >3 days 16 (7.3)
Reduced mobility >10 days 7 (3.2)
Obesity (body mass index >30 kg/m2) 98 (44.5)
Table 4. Reasons for consultation/hospitalisation (N=220)*
n (%)
Routine visit 169 (76.8)
Intercurrent trauma 1 (0.5)
Intercurrent disease potentially necessitating 
surgery/hospitalisation
18 (8.2)
Intercurrent infection 5 (2.3)
Intercurrent inflammatory disease outbreak 1 (0.5)
Intercurrent jaundice/liver or biliary tract disease 4 (1.8)
Intercurrent renal function impairment 7 (3.2)
Gestational thrombocytopenia 7 (3.2)
Gestational anaemia 13 (5.9)
Maternal constitutional haemoglobin disease 1 (0.5)
Maternofetal alloimmunisation 3 (1.4)
Gestational diabetes mellitus 28 (12.7)
Pre-existing chronic hypertension, hypertension  
in pregnancy
36 (16.4)
Placenta-mediated pregnancy complication 33 (15.0)
Pre-eclampsia 27 (12.3)
Placental abruption 6 (2.7)
Intrauterine growth restriction 11 (5.0)
Premature rupture of the membranes 2 (0.9)
Fetal distress 6 (2.7)
Pregnancy loss 8 (3.6)
Gestational week of pregnancy loss occurrence
Mean (SD) 28.8 (9.2)
Median 28.5
IQR 27.0 - 36.0
Range 9 - 38
Vaginal delivery 10 (4.5)
Caesarean delivery 42 (19.1)
Blood transfusion for postpartum haemorrhage 11 (5.0)
Postpartum wound infection 3 (1.4)
Caesarean infection 3 (1.4)
Surgical procedure (e.g. appendicectomy), pregnancy 
or puerperium
9 (4.1)
SD = standard deviation; IQR = interquartile range.
*Patients could have more than one reason for consultation/hospitalisation.
Table 5. Women at risk of VTE, stratified by risk intensity
Risk intensity n (%)
All women (N=126)
Mild 44 (34.9)
Moderate 59 (46.8)
High 23 (18.3)
Missing 1
Women during pregnancy (N=94)
Mild 40 (42.6)
Moderate 40 (42.6)
High 14 (14.9)
Missing 0
Women during the postpartum period 
(N=32)
Mild 4 (12.5)
Moderate 19 (59.4)
High 9 (28.1)
Missing 1
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postpartum in an additional 29/33 (87.9%) (95% CI 71.80 - 96.60). 
Table 6 describes the patients receiving thromboprophylaxis during 
pregnancy and the puerperium.
During pregnancy and before delivery. Some patients had multi-
ple reasons for non-prescription of thromboprophylaxis. The major 
reason for not prescribing thromboprophylaxis during pregnancy 
and before delivery was the fear of bleeding (n=24, 40.7%), followed 
by a perception of increased risk associated with thromboprophylaxis 
(negative benefit/risk ratio) (n=15, 25.4%). Fourteen of 16 patients 
(87.5%) received pharmacological thromboprophylaxis, specifically 
LMWH, during pregnancy and before delivery. Two patients received 
only mechanical thromboprophylaxis during pregnancy and before 
delivery. Table 7 details VTE prophylaxis during pregnancy and 
delivery.
During the puerperium. One hundred and four patients (96.1%) 
received prophylaxis during the puerperium (this figure includes 
those who had been at risk during pregnancy), with only 4 (3.8%) 
not receiving therapy. The reasons for not receiving therapy were 
Table 6. Prescription of thromboprophylaxis
n (%) (95% CI*)
At-risk women receiving VTE prophylaxis (N=127)
No 23 (18.1) (11.84 - 25.92)
Yes 104 (81.9) (74.08 - 88.16)
At-risk women receiving VTE prophylaxis during pregnancy (N=94)
No 19 (20.2) (12.63 - 29.75)
Yes 75 (79.8) (70.25 - 87.37)
At-risk women receiving VTE prophylaxis during the puerperium (N=33)
No 4 (12.1) (3.40 - 28.20)
Yes 29 (87.9) (71.80 - 96.60)
CI = confidence interval; VTE = venous thromboembolism.
*95% CIs calculated using the Clopper-Pearson method.
Table 7. Thromboprophylaxis during pregnancy and before delivery 
n (%)
Reason for not prescribing thromboprophylaxis during pregnancy and before delivery* (N=59)
No available proof 14 (23.7)
Financial reason 5 (8.5)
Fear of bleeding 24 (40.7)
Negative benefit/risk ratio 15 (25.4)
Other 4 (6.8)
Thromboprophylaxis received during pregnancy and before delivery (N=16)
Pharmacological treatment 14 (87.5)
Only mechanical treatment 1 (6.3)
Both 1 (6.3)
Type of pharmacological treatment during pregnancy and before delivery† (N=15)
Unfractionated heparin 0
LMWH 15 (100)
NOACs 0
Aspirin 2 (13.3)
Other 0
Duration of pharmacological treatment during pregnancy and before delivery (N=15)
Only third trimester 0
Second and third trimester 0
From now until delivery 14 (93.3)
Only during the course of the intercurrent infection 0
Only during the course of the inflammatory outbreak 0
Only during the course of the intercurrent urgent surgery 0
Only during the course of the intercurrent immobilisation 0
Only during the course of the intercurrent hospitalisation 1 (6.7)
Hospitalisation needed 0
From now until delivery + hospitalisation needed 0
Only during the course of the intercurrent urgent surgery + hospitalisation needed 0
Only during the course of the intercurrent hospitalisation + hospitalisation needed 0
If hospitalisation needed during pregnancy, thromboprophylaxis to be continued after hospital discharge (N=0) n/a
LMWH = low-molecular-weight heparin; NOACs = new oral anticoagulants; n/a = not applicable.
*More than one reason could be indicated.
†Patients could have more than one type of pharmacological treatment.
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Table 8. Thromboprophylaxis during the puerperium
Reason for not prescribing thromboprophylaxis during puerperium* (N=4), n (%)
No available proof 2 (50.0)
Financial reason 0
Fear of bleeding 1 (25.0)
Negative benefit/risk ratio 1 (25.0)
Other 0
Thromboprophylaxis received during puerperium (N=100), n (%)
Pharmacological treatment 70 (70.0)
Only mechanical treatment 0
Both 30 (30.0)
Type of pharmacological treatment during puerperium† (N=100), n (%)
Unfractionated heparin 5 (5.0)
LMWH 87 (87.0)
NOACs 8 (8.0)
Aspirin 1 (1.0)
Thromboprophylaxis for 5 - 10 days post caesarean section 34 (34.3)
Type of unfractionated heparin during puerperium (N=5), n (%)
Low dose 4 (80.0)
Intermediate dose 1 (20.0)
Weight-adjusted dose 0
Type of LMWH during puerperium (N=87), n (%)
Low dose 62 (71.3)
Intermediate dose 9 (10.3)
Weight-adjusted dose 16 (18.4)
Beginning of pharmacological treatment during puerperium (postpartum day) (N=99)
Missing 1
Mean (SD) 0.7 (0.7)
Median 1.0
IQR 0.0 - 1.0
Range 0 - 6
Duration of pharmacological treatment during puerperium (N=100), n (%)
2 weeks post partum 20 (20.0)
4 weeks post partum 1 (1.0)
6 weeks post partum 14 (14.0)
12 weeks post partum 0
5 - 10 days post caesarean section 34 (34.0)
5 - 10 days post surgery 1 (1.0)
During the course of the intercurrent infection 0
During the course of the intercurrent immobilisation 4 (4.0)
Only during the course of the intercurrent hospitalisation 10 (10.0)
Hospitalisation needed 2 (2.0)
2 weeks post partum + hospitalisation needed 3 (3.0)
4 weeks post partum + hospitalisation needed 0
6 weeks post partum + hospitalisation needed 2 (2.0)
12 weeks post partum + hospitalisation needed 1 (1.0)
5 - 10 days post caesarean section + hospitalisation needed 4 (4.0)
Only during the course of the intercurrent hospitalisation + hospitalisation needed 3 (3.0)
Missing 1
If hospitalisation needed during puerperium, thromboprophylaxis to be continued after hospital discharge 
(N=15), n (%)
No 4 (26.7)
Yes 11 (73.3)
LMWH = low-molecular-weight heparin; NOACs = new oral anticoagulants; SD = standard deviation; IQR = interquartile range.
*More than one reason could be indicated.
†Patients could have more than one type of pharmacological treatment.
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‘No available proof ’ (n=2), i.e. the investigator does not consider 
thromboprophylaxis in pregnancy as ‘valid’ and ‘recognised’, fear 
of bleeding (n=1), and perception of increased risk associated with 
thromboprophylaxis (negative benefit/risk ratio) (n=1). Seventy 
patients (70.0%) received pharmacological thromboprophylaxis and 
30 (30.0%) both pharmacological and mechanical prophylaxis in the 
puerperium. LMWH was the most commonly used pharmacological 
prophylaxis (n=87, 87%), with new oral anticoagulants (NOACs) 
(non-vitamin K antagonists) in 8 (8%). Of note, 34 (34%) received 
prophylaxis for only 5 - 10 days after caesarean section. Table 8 details 
VTE prophylaxis during the puerperium.
Risk factors determining prophylaxis
SA Asian women (n=24) were more likely to be perceived to be at 
risk of developing VTE than white women (Wald χ2 p-value 0.0316; 
odds ratio estimate 13.143; 95% CI 1.255 – 137.667). Drivers for VTE 
thromboprophylaxis included pre-eclampsia, caesarean delivery and 
immobility (Table 9).
Discussion
Drivers for VTE thromboprophylaxis included pre-eclampsia, 
caesarean delivery and immobility. The relatively low use of VTE 
thromboprophylaxis during pregnancy is concerning. Clinicians 
cited fear of bleeding and perception of an increased risk associated 
with thromboprophylaxis (negative benefit/risk ratio) during preg-
nancy as the major deterrents to using pharmacological agents 
during pregnancy. However, mechanical thromboprophylaxis was 
underutilised, with only 2 patients receiving this during pregnancy. 
The RCOG Green-top guideline[3] recommends the use of mechanical 
thromboprophylaxis for patients with a contraindication to LMWH. 
This is a grade D recommendation based on relatively less robust 
data. Mechanical thromboprophylaxis has no bleeding risk, and 
clinicians would therefore have been expected to use it in patients 
at high risk of bleeding diathesis. Non-availability of DVT stockings 
in the public health sector may have contributed to this finding. 
Research is required to determine how clinicians stratify bleeding 
risk during pregnancy.
The majority of the patients received VTE prophylaxis for only 
5 - 10 days after delivery, which is not aligned with current guide lines. 
According to the RCOG Green-top guideline,[3] thromboprophylaxis 
should be continued for 6 weeks in high-risk women and for 10 days 
in those at intermediate risk. Short duration of thromboprophylaxis 
may result in a residual risk of VTE, with potential catastrophic 
consequences. Unfortunately the study did not elucidate the reasons 
for inadequate duration of thromboprophylaxis.
LMWH was the preferred pharmacological agent for VTE 
prophylaxis. Only 8% received a non-vitamin K oral anticoagulant 
in the postpartum period. LMWH is considered the standard of care 
locally and internationally. Non-vitamin K antagonists were used in 
the minority of patients, probably because the public sector sites did 
not have access to these drugs and they should not be used during 
pregnancy and lactation[3] because their safety and efficacy during 
this period have not been established.
Snyman and Potgieter[8] investigated the VTE risk profile and 
thromboprophylaxis in 109 patients undergoing gynaecological 
surgery in a single-centre academic unit. Only 5% of study partici-
pants received the correct VTE prophylaxis. Direct comparisons 
between their study[8] and the present study cannot be made because 
they evaluated VTE in different groups of patients, i.e. gynaecological 
v. obstetric, and the doctors prescribing prophylaxis were unaware 
that they were being audited. Nevertheless, the present study had 
a higher proportion of patients receiving appropriate therapy. The 
clinicians who took part in the study are senior clinicians working in 
clinical trial sites and are therefore likely to be up to date with respect 
to guidelines. Furthermore, the study itself and the knowledge that 
they would be audited may have motivated them to better understand 
VTE risk stratification and management. These clinicians probably 
reflect the current best practices in SA.
HIV infection is increasingly being considered a prothrombotic 
state.[9] The prevalence of HIV-positive patients in this study (14.5%) 
Table 9. Significant variables in univariate analysis
OR
Variable Modality Reference Wald χ2 p-value Estimate 95% CI
Antithrombin deficiency Unknown No 0.0002 0.056 0.012 - 0.251
Caesarean delivery Yes No 0.0142 6.562 1.460 - 29.505
Emergency caesarean delivery Yes No 0.0910 5.902 0.753 - 46.238
Ethnicity Black Caucasian 0.2404 2.222 0.586 - 8.429
Other* Caucasian * *
South Asian Caucasian 0.0316 13.143 1.255 - 137.667
Factor V Leiden Unknown No 0.0003 0.063 0.014 - 0.283
Gross varicose veins Yes No 0.0783 0.370 0.122 - 1.119
Immobility Yes* No * *
Persistent beta-2-glycoprotein 1 antibodies Unknown No 0.0003 0.064 0.014 - 0.288
Persistent lupus anticoagulant Unknown No 0.0002 0.059 0.013 - 0.267
Yes* No * *
Persistent moderate/high-titre anticardiolipin 
antibodies
Unknown
Yes* 
No
No
0.0003
*
0.061
*
0.014 - 0.274
Pre-eclampsia Yes No 0.0571 7.332 0.942 - 57.092
Protein C deficiency Unknown No 0.0002 0.056 0.012 - 0.251
Protein S deficiency Unknown No 0.0002 0.056 0.012 - 0.251
Prothrombin gene 20210A allele Unknown No 0.0003 0.063 0.014 - 0.283
OR = odds ratio; CI = confidence interval.
*Quasi-complete separation of data points.
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is lower than the prevalence of ~29.7% in antenatal clinics in SA.[10] 
These figures may differ because the antenatal clinic data only 
include public sector patients.
Our cohort had a high prevalence of obesity, with 98 women 
(44.5%) having a body mass index >30 kg/m2. SA has the highest 
prevalence of obesity in sub-Saharan Africa, which may be attributed 
in part to rapid socioeconomic transition.[11] Obesity complicates 
the use of pharmacological agents, with the possibility that altered 
pharmacokinetics may require dose adjustments. In addition, obesity 
itself is a risk factor for VTE.
Study limitations
The study was limited by the small sample of clinical trial sites 
(six  sites) and the fact that the participating doctors were relative 
experts. Owing to the shortage of obstetricians and gynaecologists 
in SA, the majority of patients are treated by non-specialists whose 
adherence to guidelines may be less than ideal. The study may 
not reflect management of VTE risk during pregnancy and the 
puerperium in SA as a whole, which is dominated by a public sector 
characterised by skill shortages and high patient numbers. The study 
sites were all urban centres and therefore do not reflect rural practice. 
Despite its limitations, however, the study provides valuable insights 
into VTE risk stratification and thromboprophylaxis.
Conclusions
The doctors participating in the study were in general aware of 
VTE risk during pregnancy and the puerperium. However, VTE 
thromboprophylaxis during pregnancy could be improved. Clinicians 
cited fear of bleeding and a perception of increased risk associated 
with thromboprophylaxis (negative benefit/risk ratio) as reasons for 
not using pharmacological thromboprophylaxis during pregnancy, but 
still underused mechanical thromboprophylaxis. Patients in this study 
did not receive the recommended duration of thromboprophylaxis. 
Further research and novel methods are required to improve VTE 
prophylaxis during pregnancy and the puerperium.
We suggest the development of SA guidelines for the management 
of VTE risk during pregnancy or adoption of the current international 
guidelines (e.g. RCOG). Education of all relevant healthcare workers 
is needed regarding VTE risk stratification and management during 
pregnancy.
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